Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Mechanisms of resistance to immunotherapy in NHL

Nilanjan Ghosh • 10 Jun 2022
EHA 2022
Lymphoma Non-Hodgkin Lymphoma

Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, briefly discusses mechanisms of resistance to immunotherapy in non-Hodgkin lymphoma (NHL), drawing focus on T-cell exhaustion, myeloid-derived suppressor cells, and antigen escape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche

More from Nilanjan Ghosh

5:45
Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
6:05
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
5:42
Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL
Nilanjan Ghosh • 8 Dec 2022
5:59
InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL
Nilanjan Ghosh • 8 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals